Myriad Genetics, Inc. (LON:0K3W)

Market Cap	304.68M +7.2%
Revenue (ttm)	627.81M -0.3%
Net Income	-302.85M
EPS	-3.25
Shares Out	n/a
PE Ratio	n/a
Forward PE	39.41
Dividend	n/a
Ex-Dividend Date	n/a

Volume	455
Open	4.560
Previous Close	4.490
Day's Range	4.400 - 4.560
52-Week Range	3.532 - 8.578
Beta	1.64
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 4, 2026

About Myriad Genetics

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 1991
• Employees: 2,700
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0K3W

Financial Performance

In 2025, Myriad Genetics's revenue was $824.50 million, a decrease of -1.56% compared to the previous year's $837.60 million. Losses were -$365.90 million, 187.4% more than in 2024.

Financial numbers in USD